Abiopharma

Jounce Therapeutics Inc (the company became a subdivision of the company Concentra (Frankfurt: DI7U.F)) (JNCE) Announces Clinical Trial Update Jounce Therapeutics Inc (the company became a subdivision of the company Concentra (Frankfurt: DI7U.F)) (JNCE) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: results, vopratelimab
• Diseases/Conditions: December
• Clinical Stage: Phase 2, clinical trial
• Update Type: Trial Timeline Adjustment
• Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
• Collaboration: SELECT
  • targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.Cautionary Note Regarding Forward-Looking Statements:Various statements in this release concerning Jounce’s future expectations, plans and prospects, including without limitation, Jounce’s expectations regarding financial guidance, gross cash burn, operating expenses, capital expenditures and funding requirements; the timing, initiation or expansion, progress, results of and release of data from clinical trials of Jounce’s product candidates, including JTX-8064